JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis

  • 0Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Journal of Neuro-Oncology +

|

February 28, 2025

|

February 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Ciprofol, an anesthetic, significantly reduces glioma recurrence by inhibiting cell growth and promoting apoptosis. It targets the MAPK11-PML pathway, offering new therapeutic strategies for brain tumors.

Area Of Science

  • Neuro-oncology
  • Molecular Biology
  • Pharmacology

Background

  • Glioma is a common brain tumor with high recurrence rates after surgery.
  • Ciprofol is a known anesthetic with unexplored therapeutic potential in glioma treatment.

Purpose Of The Study

  • To investigate the therapeutic effects of Ciprofol on glioma.
  • To identify the molecular mechanisms underlying Ciprofol's action in glioma.

Main Methods

  • In vitro studies assessed glioma cell proliferation, invasion, migration, and apoptosis.
  • Proteomic, phosphoproteomic, and transcriptomic analyses identified molecular targets.
  • In vivo glioma mouse models evaluated postoperative recurrence.

Main Results

  • Ciprofol inhibited glioma cell proliferation, invasion, and migration, and induced apoptosis.
  • MAPK11 and PML were identified as key mediators of Ciprofol's effects.
  • Ciprofol reduced postoperative recurrence in vivo through MAPK11-PML phosphorylation.

Conclusions

  • Ciprofol demonstrates therapeutic potential in reducing glioma recurrence.
  • MAPK11-PML phosphorylation is a key mechanism for Ciprofol's anti-glioma effects.
  • Ciprofol offers novel molecular targets for glioma treatment beyond its anesthetic use.

Keywords: